Key statistics
On Friday, Beigene Ltd (49B:FRA) closed at 16.90, -2.31% below its 52-week high of 17.30, set on Oct 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.90 |
---|---|
High | 16.90 |
Low | 16.90 |
Bid | 16.90 |
Offer | 17.80 |
Previous close | 15.90 |
Average volume | 205.80 |
---|---|
Shares outstanding | 1.39bn |
Free float | 1.31bn |
P/E (TTM) | -- |
Market cap | 199.53bn HKD |
EPS (TTM) | -4.93 HKD |
Data delayed at least 15 minutes, as of Feb 14 2025 15:56 GMT.
More ▼
Press releases
- BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27
- BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe
- TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
- BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
- BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
- BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
- BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL
- BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024
- European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer
- BeiGene to Present at Upcoming Investor Conferences
More ▼